ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 Posted on July 13, 2021 by Derek - Press Release, Uncategorized 7.13-rNAPc2-ASPEN-COVID-Trial-Update
ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th Posted on July 9, 2021 by Derek - Press Release, Uncategorized 7.9-Access-to-Giving-Investor-Conference-FINAL
ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement Posted on July 7, 2021 by Derek - Press Release, Uncategorized 7.7-rNAPc2-Mainz-Agreement-FINAL
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update Posted on May 11, 2021 by ARCA IT - Press Release, Uncategorized 5.11-1Q2021-Financial-Results-and-Business-Update
Christopher Graybill Joins ARCA as Vice President, Clinical Development Posted on May 5, 2021 by ARCA IT - Press Release, Uncategorized 5.05-Graybill-VP-Clin-Dev
ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer Posted on May 3, 2021 by ARCA IT - Press Release, Uncategorized 5.03-CFO-Transition
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update Posted on March 18, 2021 by ARCA IT - Press Release, Uncategorized 1.18-2020-Financial-Results-and-Business-Update
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 Posted on December 15, 2020 by ARCA IT - Press Release, Uncategorized 12.15-rNAPc2-FPE-ASPEN-COVID-Trial
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders Posted on December 9, 2020 by ARCA IT - Press Release, Uncategorized 12.9-ARCA-Annual-Meeting-Location-Change-FINAL
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation Posted on November 23, 2020 by ARCA IT - Press Release, Uncategorized 11.23-AB201-COVID-FDA-Fast-Track-Designation